A5043012263- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Acute Myocardial Infarction Research
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac pacing and defibrillation studies
- Potassium and Related Disorders
- Sepsis Diagnosis and Treatment
- Acute Kidney Injury Research
- Cardiac Imaging and Diagnostics
- Hemodynamic Monitoring and Therapy
- Atrial Fibrillation Management and Outcomes
- Cardiac Fibrosis and Remodeling
- Mechanical Circulatory Support Devices
- Congenital Heart Disease Studies
- Electrolyte and hormonal disorders
- IL-33, ST2, and ILC Pathways
- Emergency and Acute Care Studies
- Neuropeptides and Animal Physiology
- Cardiac Arrest and Resuscitation
- Dialysis and Renal Disease Management
- Galectins and Cancer Biology
- Cardiac electrophysiology and arrhythmias
- Cardiac Valve Diseases and Treatments
- Receptor Mechanisms and Signaling
- GDF15 and Related Biomarkers
San Francisco VA Medical Center
2008-2025
University of California, San Diego
2015-2024
Vanderbilt University
2023
Montreal Heart Institute
2023
VA San Diego Healthcare System
2013-2022
University of San Diego
1990-2022
Massachusetts General Hospital
2012-2022
Cardiovascular Research Center
2022
Veterans Health Administration
2004-2021
Charité - Universitätsmedizin Berlin
2009-2021
B-type natriuretic peptide is released from the cardiac ventricles in response to increased wall tension.
Background — We sought to determine the degree which B-type natriuretic peptide (BNP) adds clinical judgment in diagnosis of congestive heart failure (CHF). Methods and Results The Breathing Not Properly Multinational Study was a prospective diagnostic test evaluation study conducted 7 centers. Of 1586 participants who presented with acute dyspnea, 1538 (97%) had certainty CHF determined by attending physician emergency department. Participants underwent routine care BNP measured blinded...
Although Doppler echocardiography has been used to identify abnormal left ventricular (LV) diastolic filling dynamics, inherent limitations suggest the need for additional measures of dysfunction. Because data that B-natriuretic peptide (BNP) partially reflects pressure, we hypothesized BNP levels could predict abnormalities in patients with normal systolic function.We studied 294 referred evaluate function. Patients function were excluded. Cardiologists making assessment LV blinded levels....
In patients with heart failure and reduced ejection fraction (HFrEF), treatment sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of on cardiac remodeling is uncertain.To determine whether NT-proBNP changes in HFrEF treated correlate measures volume function.Prospective, 12-month, single-group, open-label study enrolled 78 outpatient sites the United States. Sacubitril-valsartan was initiated dose adjusted. Enrollment commenced...